| The oncogenic 70Z Cbl mutation blocks the phosphotyrosine binding domain-dependent negative regulation of ZAP-70 by c-Cbl in Jurkat T cells. | None |
| The Cbl proto-oncogene product negatively regulates the Src-family tyrosine kinase Fyn by enhancing its degradation. | None |
| A Drosophila analogue of v-Cbl is a dominant-negative oncoprotein in vivo. | None |
| c-Cbl is a suppressor of the neu oncogene. | None |
| The proto-oncogene c-Cbl is a positive regulator of Met-induced MAP kinase activation: a role for the adaptor protein Crk. | None |
| The adapter type protein CMS/CD2AP binds to the proto-oncogenic protein c-Cbl through a tyrosine phosphorylation-regulated Src homology 3 domain interaction. | None |
| Suppression of apoptosis induced by growth factor withdrawal by an oncogenic form of c-Cbl. | None |
| The involvement of the proto-oncogene p120 c-Cbl and ZAP-70 in CD2-mediated T cell activation. | None |
| Isolation and characterization of a novel, transforming allele of the c-Cbl proto-oncogene from a murine macrophage cell line. | None |
| Isolation and characterization of a novel, transforming allele of the c-Cbl proto-oncogene from a murine macrophage cell line. | None |
| The multi-adaptor proto-oncoprotein Cbl is a key regulator of Rac and actin assembly. | None |
| Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors. | None |
| Ephrin-A1 stimulation of Jurkat T cells induces tyrosine phosphorylation of EphA3 receptors and cytoplasmic proteins, including c-cbl proto-oncogene, and causes down-regulation of endogenous EphA3 receptors from the cell surface and their degradation. | None |
| A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. | None |
| Androgen-dependent apoptosis in male germ cells is regulated through the proto-oncoprotein Cbl. | None |
| Mapping minimally overlapping segmental UPD regions helps target the search for pathogenic mutations, including newly identified missense mutations in the proto-oncogene c-Cbl in 7 of 12 patients with UPD11q. | None |
| 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. | None |
| The c-Cbl proto-oncoprotein downregulates EBV LMP2A signaling. | None |
| Epidermal Growth Factor stimulation increases association of Cbl and Ruk/CIN85, which is dependent on tyrosine phosphorylation of the C-terminal region of Proto-Oncogene Proteins Cbl. | None |
| Intersectin 1 forms a complex with adaptor protein Ruk/CIN85 in vivo independently of epidermal growth factor stimulation. | None |